Ocular Therapeutix (OCUL) Sees Large Volume Increase
Ocular Therapeutix Inc (NASDAQ:OCUL) shares saw unusually-strong trading volume on Friday . Approximately 984,482 shares traded hands during mid-day trading, an increase of 196% from the previous session’s volume of 332,887 shares.The stock last traded at $5.60 and had previously closed at $4.91.
A number of analysts have issued reports on OCUL shares. ValuEngine lowered Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a report on Thursday, September 21st. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a report on Monday, September 25th. Guggenheim began coverage on Ocular Therapeutix in a report on Monday, October 23rd. They set a “buy” rating and a $12.00 price objective on the stock. Zacks Investment Research lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $20.67.
The firm has a market cap of $164.85, a price-to-earnings ratio of -2.46 and a beta of 1.32. The company has a quick ratio of 4.78, a current ratio of 4.79 and a debt-to-equity ratio of 0.39.
In other news, Chairman Amarpreet Sawhney acquired 19,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were bought at an average price of $5.18 per share, with a total value of $98,420.00. Following the acquisition, the chairman now owns 696,390 shares of the company’s stock, valued at $3,607,300.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Antony C. Mattessich bought 21,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The shares were bought at an average price of $4.29 per share, with a total value of $90,090.00. Following the transaction, the insider now directly owns 21,000 shares in the company, valued at $90,090. The disclosure for this purchase can be found here. Insiders have bought a total of 69,500 shares of company stock worth $304,781 in the last three months. 26.10% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Hikari Power Ltd bought a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $356,000. Northern Trust Corp lifted its position in shares of Ocular Therapeutix by 13.2% during the 2nd quarter. Northern Trust Corp now owns 262,139 shares of the biopharmaceutical company’s stock worth $2,430,000 after buying an additional 30,539 shares during the period. State Street Corp lifted its position in shares of Ocular Therapeutix by 12.3% during the 2nd quarter. State Street Corp now owns 371,923 shares of the biopharmaceutical company’s stock worth $3,450,000 after buying an additional 40,782 shares during the period. Neuberger Berman Group LLC bought a new position in shares of Ocular Therapeutix during the 2nd quarter worth approximately $277,000. Finally, Parametric Portfolio Associates LLC lifted its position in shares of Ocular Therapeutix by 97.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 60,519 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 29,937 shares during the period. Institutional investors and hedge funds own 52.94% of the company’s stock.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.